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Abstract
Objectives Photodynamic therapy is a new focal therapy for
prostate cancer.
Methods In this technique, a photosensitising agent is intro-
duced intravenously, then activated by local laser illumination
to induce tumour necrosis. Treatment efficacy is assessed by
magnetic resonance imaging (MRI).
Results and Conclusions We illustrate specific post-treatment
MRI aspects at early and late follow-up with pathological
correlations.
Teaching points
•Dynamic phototherapy is a new and promising focal therapy
for prostate cancer.
• One-week MRI shows increased volume of the treated lobe
and large, homogeneous necrosis area.
• Six-month MRI shows significant changes of the prostate
shape and signal.
• Six-month MRI becomes “base line” appearance for further
follow-up or monitoring.
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Introduction
In 2012, with 417,000 new cases and 92,200 deaths, prostate
cancer was the third most common cancer in Europe overall
after female breast cancer and colorectal cancer [1]. In men
only it was the most common cancer, followed by lung and
colorectal cancers. The incidence of prostate cancer, especial-
ly for localised disease, has been growing since the 1990s, a
dynamic that may be attributable to the widespread use of
prostate-specific antigen (PSA) tests [2] and increasing life
expectancies.
The management of prostate cancer is still under debate in
the urological community. Radical prostatectomy, external
beam radiotherapy or brachytherapy are still considered
gold-standard treatments, but carry with them well-known
side effects (urinary incontinence, erectile dysfunction, intes-
tinal toxicity). Active surveillance and watchful waiting are
attractive options for localised tumours [3]. Various focal
treatments, such as phototherapy, cryotherapy, interstitial
thermotherapy and dynamic high-frequency ultrasound
(HIFU), are being evaluated [4, 5].
Photodynamic therapy is a recent technology wherein a
photosensitising agent (WST11) is administered intravenous-
ly, then activated by light to induce tumour necrosis. The light
is applied using laser optical fibres positioned within the
prostate as determined by magnetic resonance imaging
(MRI) planning. The procedure is performed under general
anaesthesia, in the dark. Hollow, transparent, plastic brachy-
therapy catheters were positioned into the prostate, using
TRUS-image guidance in accordance with a previously de-
vised MRI-based treatment plan (Fig. 1). Cylindrically diffus-
ing optical fibres were inserted into the catheters. Laser light
was delivered to the prostate, using a multichannel diode laser.
The single TOOKAD Soluble intravenous (i.v.) dose was a
10-min infusion, followed by continuous illumination of the
prostate gland for between 20 and 25 min. The total duration
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of the whole procedure was~2 h. The light activates the
photosensitiser in the prostate, generating reactive oxygen
species that activate thrombosis within the vessels. This re-
sults in obliteration of the microvessel anatomy with resultant
deprivation of oxygen and nutrients to the tumour cells and
surrounding prostate tissue in the treated area [6–8]. An opti-
mal radius of 6.5 mm is expected around a 753-nm laser fibre
[9]. The treatment appears promising for localised prostate
cancer and benefits from a reasonably low rate of complica-
tions [10]. Currently, MRI is the reference imaging technique
Fig. 1 Procedure performed under general anaesthesia, in the darkness (a). Catheters were positioned into the prostate, using TRUS-image guidance in
accordance with a previously devised MRI-based treatment plan. Cylindrically diffusing optical fibres were inserted into the catheters (b)
Fig. 2 Pre-treatment MRI of a
65-year-old patient with a PSA
level of 9.7 ng/ml and a positive
biopsy in the right prostate apex
(adenocarcinoma Gleason 6).
Axial and sagittal T2-weighted
images (a, b) show a hypointense
nodule in the right peripheral
prostate with restriction on the
apparent diffusion coefficient
map of the diffusion-weighted
image (c, low signal intensity)
and early enhancement on the
axial dynamic contrast-enhanced
MR image (d, arrowhead)
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for the diagnosis of disease and follow-up after local treatment
[11–13].
However, the changes induced by photodynamic therapy
are poorly reported in the literature. Thus in the present
pictorial review, we illustrate various MRI features in the
follow-up of patients who underwent photodynamic therapy
for localised prostate cancer. We studied early and late normal
aspects, local complications and aspects of recurrence, with
histopathological correlation.
Iconography and imaging protocol
The iconography presented in this paper comes from a group
of 77 patients enrolled by our institution in a prospective
international multicentric study (phase II/III), and who re-
ceived photodynamic therapy with WST11 (Tookad soluble)
for localised prostate cancer.
Inclusion criteria are: men over 18 years old; diagnosed
prostate cancer histologically proved on biopsies (systematic
biopsies most of the time, rarely targeted biopsies); eligible for
active surveillance; no prior treatment for prostate cancer;
TNM stage up to cT2b- N0/Nx- M0/Mx; Gleason score≤3+
3, 3+4 accepted in certain conditions; PSA<10 ng/ml. The
prostate cancer diagnosis was histological. All patients had a
pre-treatment MRI then post-treatment MRIs at 1 week (early
post-treatment) and 6 months (late post-treatment). Some of
the patients also had a post-treatment MRI at 3 months. Sys-
tematic biopsies with TRUS (trans-rectal ultrasound)
Fig. 3 Oedema and necrosis. Left lobe photodynamic therapy in a 65-
year-old patient with a PSA level of 6.2 ng/ml and two positive biopsies
in the left lobe—Gleason 6 (3+3) adenocarcinoma. a Pre-treatment axial
T2-weighted image shows diffuse bilateral hyposignal of the peripheral
prostate without focal nodularity. b Day-7 post-treatment axial T2-
weighted image shows a heterogeneous signal of the treated lobe extend-
ing to the peripheral and transitional zone (arrowhead). Note that the
signal of the right lobe peripheral zone is unchanged compared with the
pre-treatment image
Fig. 4 Volume increase of the treated lobe. A 65-year-old patient with a middle right lobe positive biopsy. Pre-treatment axial T2 sequence (a) shows a
normal prostate. Axial (b) and coronal (c) day-7 post-treatment T2-weighted images show an asymmetrical increase of the volume of the treated lobe (star)
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guidance were performed at 6 months to explore correlations
to MRI features. In case of positive biopsy at 6 months,
function of the Gleason score, different options were proposed
to the patients: treatment of the other lobe, retreatment on the
same lobe, active surveillance or surgery.
MRI protocol
All MRIs were performed with a 1.5-T MRI system (GE
Excite, General Electrics, Milwaukee, IL). An external body
surface coil (eight channels) was used, with a field of view
(FOV) equal to 24 cm, except for the dynamic contrast-
enhanced sequences for which FOV was 42 cm.
The imaging protocol included the following sequences:
axial and coronal FRFSE T2 with fat saturation (4-mm slice
thickness), axial FSE T1 (4-mm slice thickness), axial
diffusion-weighted (b=600 s/mm2); a three-dimensional
(3D) dynamic contrast-enhanced T1 sequence (LAVA) with
fat saturation after intravenous injection of 20 ml gadoterate
meglumine (Dotarem, Guerbet, France), followed by axial
and sagittal fat saturation contrast-enhanced FSE T1-
Fig. 5 Path of optical fibres. Right prostate lobe treatment for adenocar-
cinoma Gleason 6 (3+3) in a 62-year-old patient with a PSA level of
9 ng/ml. Tumour was not visible on pre-treatment MRI. The paths of the
optical fibres in the treated area are visible on the day-7 post-treatment
axial T2-weighted image (a) as small hyperintense spots corresponding to
thin linear bands (star) in the coronal view (b)
Fig. 6 Haemorrhage within treated lobes is variable. a Day-7 post-
treatment axial T1 MR image in a 64-year-old patient with right lobe
photodynamic therapy shows an asymmetric prostate (star) with in-
creased volume of the treated lobe but without any spontaneous high
signal intensity evoking haemorrhage in the treated area. b A 72-year-old
patient with left lobe treatment. Day-7 post-treatment axial T1 shows a
hyperintense area (arrowhead) corresponding to post-treatment
haemorrhagic suffusions. c Right lobe phototherapy in a 59-year-old
patient. Day-7 post-treatment axial T1-weighted MR image shows a
spontaneous high-signal-intensity area in the right lobe (arrowhead),
but also an extended spontaneous high signal intensity in the left
(untreated) lobe (star)
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Fig. 7 Well-defined necrosis boundaries. A 72-year-old patient with a
PSA level of 4.5 ng/ml treated for Gleason 6 (3+3) left lobe adenocarci-
noma. Axial dynamic contrast-enhanced images before treatment (a)
show a zone of post-biopsy haemorrhage on the right lobe without any
suspicious enhancement. Day-7 post-treatment left MRI (b) shows no
enhancement of the left treated lobe (necrosis). Note the extended
periprostatic enhancement that surrounds the whole gland and indicates
inflammation. Right lobe treatment for Gleason 6 adenocarcinoma: day-7
post-treatment axial (c) and sagittal (d) FS contrast-enhanced images
show a large homogenous hypointense non-enhanced area in the treated
lobe (necrosis) with well-defined and highly enhanced boundaries
Fig. 8 Focal spared tissue. Left
lobe photodynamic therapy in a
66-year-old patient. Axial T1 (a)
and contrast-enhanced axial T1
FS (b) images show islands of
spared tissue (arrowhead) that
enhance within the treated area
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Fig. 9 Suspected residual tumour. Day-7 post-treatment dynamic
contrast-enhanced fat-saturated axial T1-weighted MR image showing
early nodular enhancement in the prostate apex suggestive of residual
tumour away from the treated area. Diffusion-weighted MRI was not
contributive. The nodule was no longer visible on the 3-month post-
treatment and 6-month post-treatment MRIs, and the 6-month post-treat-
ment biopsy was negative
Fig. 10 Periurethral
enhancement ring. Day-7 post-
treatment axial T1 FS contrast-
enhanced MR images for a
bilaterally treated patient show
necrosis in both lobes. The
intraprostatic urethra presents a
continuous enhancement ring (a).
A rupture of this ring
enhancement (arrowhead) after
photodynamic therapy is
considered suspicious of urethral
wall necrosis (b). No urinary
complications were identified in
this patient during close clinical
follow-up
702 Insights Imaging (2014) 5:697–713
weighted images. These last sequences were systematically
realised, to better define boundaries of necrosis, especially in
case of extra prostatic necrosis.
Pre- and post-treatment MRI exams were analysed on an
imaging work station (Fujifilm Synapse 3D). We analysed
MRI modifications for the areas treated with photodynamic
therapy (optical fibre disposition map) and the histopatholog-
ical results of systematic 6-month biopsies. Some patients
underwent prostatectomy after the phototherapy treatment,
permitting a more accurate radiological-pathological
correlation.
PIRADS classification was not used for treatment plan-
ning. Pre-treatment MRI served only to plan the anatomic
distribution of the optic fibres into the lobe to be treated,
targeting the zones of positive biopsy. The PIRADS criteria
were used for the follow-up MRI analyses.
Pre-treatment MRI
Pre-treatment MRI was performed as a planning procedure to
determine the position and the number of optical fibres and to
exclude any loco-regional extension that would have contra-
indicated the treatment.
Only small tumours with low aggressiveness (Gleason 6)
were considered for photodynamic therapy and thus not all of
them were visible. When tumours were visible, the classical
aspect was a hypointense nodule in T2-weighted MR images,
with restriction on the apparent diffusion coefficient map and
early enhancement on dynamic contrast-enhancedMR images
(Fig. 2).
Early post-treatment MRI features
One-week MRI examinations show T2 heterogeneous signals
in the treated lobes (Fig. 3) that are related to the oedema and
ischaemic modifications induced by phototherapy. These
modifications are secondary to local intravascular coagulation
triggered by the photosensitising agent when exposed to laser
light.
MRI sequences show an increased volume of the treated
lobe. When the procedure is unilateral, the volume variation is
obvious and particularly well visualised in T2-weighted
Fig. 11 Residual necrosis. Six-
month post-treatment MRI in a
patient treated by left
photodynamic therapy. Axial T1
FS contrast-enhanced (a) and
axial T2-weighted images (b)
show persistence of a low signal
intensity area with no
enhancement (arrowhead)
corresponding to a small area of
residual necrosis (coagulation
necrosis). Pathology slides from
biopsy at low (c) and high
magnification (d) show loose
connective tissue coreless, with
cell ghosts, characteristic of
coagulation necrosis
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sequences (Fig. 4) because of their clear delineation of pros-
tate borders.
Among all heterogeneities within the treated lobe, besides
the loss of physiological distinction between transitional and
peripheral prostate tissue in T2 images, the paths of the optical
fibres can be observed as small hyperintense spots in the axial
plane and linear bands in the sagittal and coronal planes
(Fig. 5).
On T1-weighted images before gadolinium injection, hy-
perintense, poorly defined areas can be identified. These areas
Fig. 12 Fibrous scar. Axial T2-
weighted MR (a) and axial T1 FS
contrast-enhanced (b) images, in
a case of bilateral photodynamic
therapy show a post-treatment
pattern, with a small area of low
signal intensity, without
enhancement, corresponding to
fibrous scar tissue (arrowhead).
Low power (c, d) images from
radical prostatectomy show a
focus of sclerotic and hyaline
necrosis on the left lobe
suggesting a 7 × 5-mm therapy
scar
Fig. 13 Residual fluid cavity.
Six-month post-treatment follow-
up MRI in a patient with left
photodynamic therapy. Axial T2-
weighted (a) and T1-weighted (b)
MR images show an irregularly
shaped residual fluid cavity in the
treated lobe, with a low signal on
T1 (arrowhead) and a high signal
on T2
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are related to haemorrhagic suffusions (Fig. 6) and make T1-
weighted contrast-enhanced images difficult to analyse; in this
situation the use of image subtraction may be helpful.
Necrosis is best defined on T1-weighted FAT-SAT
contrast-enhanced images. It appears as non-enhancing
areas [14] with irregular but well-defined and highly
enhanced edges (Fig. 7). In most cases, a treated lobe
presents a single, large, homogeneous necrosis area on
T1 contrast-enhanced sequences. However, in some
cases, islands of spared tissue may be observed with
high early enhancement (Fig. 8). This aspect should not
be wrongly analysed as residual tumour [14].
Fig. 14 Asymmetry/symmetry.
Axial T2-weighted MR images
from before treatment (a) and
6 months after treatment (b) in a
65-year-old patient with left
unilateral photodynamic therapy
illustrate post-treatment
asymmetric prostate due to
unilateral scar tissue. However,
pre-treatment (c) and 6-month
post-treatment (d) MRIs in a case
of bilateral treatment (71-year-old
patient) illustrate a symmetrical
aspect. Note the disappearance of
the peripheral zone of the treated
lobes on the 6-month MRIs
Fig. 15 Unchanged scar
appearance over time. Six-month
post-treatment axial T2 images in
a 66-year-old left photodynamic
therapy patient show left lobe
atrophy (particularly for the
peripheral prostate) as well as a
small fluid cavity (arrowhead) in
the middle of the scar. There was
no change in this aspect at 1 year
(b)
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Another pitfall to be avoided is focal inflammatory en-
hancements in the treated lobe presenting a nodular feature
(Fig. 9). These lesions are usually no longer present on 3-
month post-treatment MRIs.
In cases with concomitant bilateral treatment, the 1-week
MRI shows the same types of modifications but they are
symmetrical. A particularity of bilateral treatment is the higher
risk of urethral wall necrosis. Normally, the intraprostatic
urethra exhibits a continuous ring of peripheral enhancement
[14]. A discontinuous ring (Fig. 10) on the 1-week post-
photodynamic therapy MRI is thus suggestive of urethral wall
necrosis. In this situation, despite earlier animal studies
reporting structural and functional resistance of the urethra
to photodynamic therapy [15], close clinical monitoring is
essential.
Finally, it is important to note that on the 1-week post-
therapy images the surroundings of the gland may also show
enhancement due to local inflammation.
Fig. 16 Unchanged scar
appearance over time. Six-month
(a) and 3-year (b) post-treatment
MRI for right photodynamic
therapy. The 6-month and 3 year
axial T2-weighted images show
the same aspect: atrophy of the
right lobe with attraction of the
urethra, and the disappearance of
normal peripheral prostate
hyperintensity. Treatment resulted
in a lesser modification of the
transitional zone compared with
the contralateral lobe
Fig. 17 Three-month post-treatment MRI in a 69-year-old patient with
concomitant bilateral treatment for prostate adenocarcinoma, Gleason 6
(PSA level of 8.14 ng/ml, 1/12 positive biopsy at right apex). Axial T1 FS
contrast-enhanced image (a) shows the persistence of two small areas of
residual necrosis (arrowhead)
Fig. 18 Retreatment of the same lobe. A 60-year-old patient with
retreatment of the right lobe. Day-7 post-retreatment axial T2-weighted
MR image (a) and axial T1 FS contrast-enhanced MR image (b) show a
slight volume increase of the treated lobe compared with the first
procedure; the area of prostate necrosis presents two different intensity
levels: the residual fluid cavity (arrowhead) and tissue necrosis (arrow),
with less low intensity. Note, 6 months post first treatment axial T2-
weighted MR image (c) corresponding to pre-retreatment aspect
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Late post-treatment MRI features
At 6 months after photodynamic therapy, important changes
of the prostate shape and signal are found. Small areas of
residual necrosis may still be present in the treated lobe,
corresponding to coagulation necrosis (Fig. 11).
Classically, the volume of the treated lobe decreases, some-
times to less than the volume of the lobe before treatment. This
is due to the apparition of retractile fibrous scar tissue
(Fig. 12).
Residual, irregularly shaped fluid cavities related to
atrophy in the treated lobe are frequently seen (Fig. 13).
Fig. 19 Contralateral treatment. A 56-year-old patient, with initial right
photodynamic therapy, then left therapy in a second intervention. Pre-left
therapy (a) and day-7 post-left therapy (b) axial T2-weighted images;
day-7 post-left therapy (c) axial T1 FS contrast-enhanced MR image. On
the left lobe, a heterogeneous T2 area with low signal in T1-weighted
image, unenhanced, corresponding to the recent tissue necrosis (star). In
the right lobe the T2 hyperintense old cystic cavity increased in size
(arrowhead)
Table 1 Treatment-emergent adverse events (TEAEs) of photodynamic
therapy. Data from Azzouzi et al. study [8]
Mild TEAE Serious TEAE
Dysuria Prostatitis
UTI (urinary tractus infection) Haematuria
Urinary retention Epididymo-orchitis
Constipation Cystoprostatitis
Perineal pain Ischaemic optic neuropathy
Inflammatory prostatic cyst
Fig. 20 Periprostatic fatty tissue. A 62-year-old patient who had
underwent left photodynamic therapy 1 year earlier, and right treatment
7 days earlier. Axial T1-weighted (a), axial T1 FS unenhanced (b) and
contrast-enhanced (c) images show a nodular lesion (arrowhead) located
in the right rectoprostatic angle, with a high intensity T1 FS signal,
unenhanced, corresponding to focal haemorrhagic necrosis of
periprostatic fatty tissue
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On T2-weighted images, the normal hypersignal of the
peripheral prostate is replaced by the irregular
hyposignal of the scar.
Unilateral treatment induces an asymmetric prostate,
whereas bilateral treatment results in a small, heterogeneous,
but symmetrical prostate (Fig. 14).
Fig. 21 Levator ani muscle.
Right photodynamic therapy in a
65-year-old patient for Gleason 6
adenocarcinoma (two positive
biopsies in right prostate). Day-7
post-treatment axial (a) and
coronal (b) T2-weighted MR
images visualise a heterogeneous
high signal of the right
puborectalis muscle
(arrowheads); axial and sagittal
T1 FS contrast-enhanced images
(c, d) show a low-signal well-





the right levator ani muscle
Fig. 22 Levator ani muscle. Day-7 post-treatment axial T1 FS contrast-
enhanced (a) and axial T2-weighted (b) MR images after right photody-
namic therapy show extension of necrosis to puborectalis muscle (star); at
the 6-month post-treatment MRI follow-up, the axial T2 image (c) illus-
trated the complete disappearance of the area of necrosis (arrowhead). No
anal functional abnormalities were seen in this patient
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Furthermore, the aspect observed at 6 months is definitive
(Figs. 15 and 16). We thus underline that the 6-month MRI is
very important as it will become the new “base line” appear-
ance for any further follow-up or monitoring.
Three-month MRIs are not pertinent for treatment follow-
up as they tend to show aspects that are between early necrosis
and late fibrosis and thus difficult to analyse (Fig. 17).
Post-retreatment features
The indication criteria of retreatment are positive biop-
sies in treated or contralateral lobe during the follow-up,
with Gleason score≤3+3 or 3+4 in certain conditions.
When ipsilateral retreatment is needed, the modifications
seen after 1 week are similar to those seen 1 week after
the initial treatment (Fig. 18). After 6 months, the
atrophy in the retreated lobe is more marked than after
the first treatment.
When a renewed intervention is for the contralateral lobe
(Fig. 19) the asymmetric aspect is more pronounced at 1 week
because of the atrophy of the previously treated lobe, but at
6 months, this asymmetry disappears and the prostate takes on
the same appearance as a concomitant bilateral treatment.
Complications
Photodynamic therapy appears to have a reasonably low rate
of complications [10]. In a study on different types of focal
therapies performed in a cohort of men with low-risk prostate
cancer, the overall complication rate was 13 %, with only two
Clavien-Dindo grade 3 complications. (Clavien Dindo is a
Fig. 23 Internal obturator muscle. Left photodynamic therapy in a 66-
year-old patient with Gleason 6 adenocarcinoma (pre-treatment/day-7
post-treatment/6-month post-treatment). Axial (a) and coronal (b) T2-
weighted MR images show high signals of the left internal obturator
muscle (arrowhead) and the puborectalis muscle (arrow). Extraprostatic
necrosis extending to muscles is well defined on the T1 FS contrast-
enhanced image (c, flash)
Fig. 24 Anterior rectal wall. Right focal treatment for adenocarcinoma in
a 65-year-old patient. Day-7 post-treatment (a) and 6-month post-treat-
ment (b) axial T1 FS contrast-enhancedMR images show the presence of
a thin line of necrosis extending to the anterior rectal wall (arrow), limited
to the muscularis propria. Note the complete recovery of the rectal wall at
6 months. Also no fistulae were clinically identified
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grading system from 1 to 5, used for the classification of
surgical complications; grade 3 or more are serious complica-
tions: grade 3—complication which requires surgical, endo-
scopic or radiological intervention—up to grade 5, which
corresponds to the death of the patient). In that series, there
were no complications described for the patients who received
photodynamic therapy [16]. Azzouzi et al. [8] found that most
treatment-emergent adverse events (TEAEs) post photody-
namic therapy were mild or moderate and only 9 % of patients
reported serious TEAEs (Table 1).
The main post-photodynamic therapy complication is
extraprostatic necrosis, defined as a lack of enhancement on
T1-weighted contrast-enhanced MR images [14] involving
the different structures surrounding the prostate.
When present, necrosis most frequently extends to
periprostatic fatty tissue (Fig. 20). The muscles close
to the prostate can also be affected, especially the leva-
tor ani (Fig. 21). However, in our experience with this
situation, anal functional abnormalities are not observed
and a normal aspect is recovered after 6 months
(Fig. 22).
Extraprostatic necrosis may also affect the internal obtura-
tor muscle (Fig. 23) and rarely it may extend to the anterior
rectal wall (Fig. 24). In our experience, fistulisation does not
seem to occur and the rectal wall recovers its normal aspect on
the 6-month follow-up MRI.
Sliding of the optical fibre may result in an extension to a
seminal vesicle (Fig. 25).
Fig. 26 Urethral necrosis. Right photodynamic therapy in a 60-year-old
patient with a PSA level of 12.9 ng/ml and Gleason 6 adenocarcinoma
(positive base biopsies, right middle prostate). Day-7 post-treatment axial
(a) and sagittal (b) T1 FS contrast-enhanced MR images do not show the
normal periurethral ring of enhancement; the patient developed acute
urinary retention treated by urinary catheter
Fig. 25 Seminal vesicle. Left photodynamic therapy in a 56-year-old patient. Day-7 post-treatment axial (a) and sagittal (b) T1 FS contrast-enhanced
MR images show a small extension of necrosis to the left seminal vesicle (arrowhead) by extraprostatic sliding of an optical fibre
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Fig. 28 Recurrence seen on
MRI. Right photodynamic
therapy in a patient with Gleason
6 adenocarcinoma. Six-month
post-treatment axial T2 (a) image
shows a hypointense nodule of
the right peripheral prostate and
the axial dynamic contrast-
enhanced (b) image illustrates an
early enhancement after gadolini-
um injection of the nodule sug-
gestive of recurrence
(arrowhead). Low-power (c) and
high-power (d) pathology slides
of a right base prostate biopsy
show small irregular glands lined
by a single layer of cells,




Fig. 27 Small recurrence not seen on MRI. Patient with a positive right
base prostate biopsy (3-mm focus). Six-month post-treatment axial T2-
weighted (a) and axial dynamic contrast-enhanced (b) images show
atrophy of the right lobe including the peripheral prostate; no suspicious
nodules are visible. Pathology slide at high magnification (c) of a right
base prostate biopsy, shows a small glandular focus (circled) between
normal glands, lined by a single layer of cells
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As mentioned earlier, necrosis may affect the intraprostatic
urethra; a break of the periurethral enhancement ring or its
complete disappearance at 1 week is an interesting sign sug-
gestive of urethral parietal necrosis (Fig. 26).
Recurrence in the treated area
MRI detection of tumour recurrence in the treated area is made
difficult by the loss of the normal hyperintensity of the pe-
ripheral prostate in T2-weighted images and the signal of the
scar.
Thus, after photodynamic therapy, the diagnosis of recur-
rence is mainly based on PSA levels and systematic biopsy.
There is no reliable feature of recurrence and cases of small
unaggressive recurrence are usually not visible on MRI
(Fig. 27). Early dynamic contrast-enhanced images and ap-
parent diffusion coefficient mapping may be useful for detect-
ing recurrence (Fig. 28) but they lack reliability. Therefore,
any suspicious nodule seen on follow-up MRI should be
biopsied (Fig. 29). Targeted biopsies with TRUS are per-
formed in nodules presenting PIRADS criteria on follow-up
MRI.
Conclusions
Photodynamic therapy is a new and promising focal
treatment for localised prostate cancer. Early and late
post-treatment MRI aspects are specific. Necrosis is
obtained at 1 week and the final post treatment aspect
at 6 months. Knowledge of these features permits the
appreciation of treatment efficacy and the accurate di-
agnosis of complications or recurrence.
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reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J et al (2013) Cancer
incidence and mortality patterns in Europe: estimates for 40 countries
in 2012. Eur J Cancer Oxf Engl 49:1374–1403
Fig. 29 Mismatch. PSA increase
in a patient treated by left
photodynamic therapy 1 year
earlier. MRI was performed: axial
T2 (a), axial ADC (b) and axial
T1 dynamic contrast-enhanced (c)
MR images show a suspicious left
median focus with T2 hyposignal,
early enhancement and mild
diffusion restriction on ADC map
(arrowhead). The location of
suspicious lesion seen on MRI is
indicated on a prostate map.
Targeted biopsy was performed
with TRUS. Pathology slide at
high magnification (d) shows a 1-
mm tumour focus in a scar tissue.




surrounded by thick collagen
fibres (fibrous scar). The nodule
on MRI corresponds to the scar
tissue; the tumour focus is too
small to be seen on MRI
712 Insights Imaging (2014) 5:697–713
2. Stattin P, Holmberg E, Johansson J-E et al (2010) Outcomes in
localized prostate cancer: National Prostate Cancer Register of
Sweden follow-up study. J Natl Cancer Inst 102:950–958
3. Parker C (2004) Active surveillance: towards a new paradigm in the
management of early prostate cancer. Lancet Oncol 5:101–106
4. Marberger M, Carroll PR, Zelefsky MJ et al (2008) New treatments
for localized prostate cancer. Urology 72:S36–S43
5. Valerio M, Ahmed HU, Emberton M et al (2013) The role of focal
therapy in the management of localised prostate cancer: a systematic
review. Eur Urol pii:S0302-2838(13)00557-5
6. Ficheux H (2009) Photodynamic therapy: principles and therapeutic
indications. Ann Pharm Fr 67:32–40
7. Henderson BW, Dougherty TJ (1992) How does photodynamic
therapy work? Photochem Photobiol 55:145–157
8. Azzouzi A-R, Barret E, Moore CM, et al.(2013) TOOKAD(®)
Soluble vascular-targeted photodynamic (VTP) therapy: determina-
tion of optimal treatment conditions and assessment of effects in
patients with localised prostate cancer. BJU Int.112:766–774
9. Betrouni N, Lopes R, Puech P, Colin P, Mordon S (2011) A model to
estimate the outcome of prostate cancer photodynamic therapy with
TOOKAD Soluble WST11. Phys Med Biol 56:4771
10. Challacombe BJ, Murphy DG (2013) Focal therapy in the treatment
of localised prostate cancer: primum non nocere. Eur Urol 63:623–
624, discussion 625–626
11. Vargas HA, Wassberg C, Akin O, Hricak H (2012) MR imaging of
treated prostate cancer. Radiology 262:26–42
12. Bratan F, Niaf E,Melodelima C et al (2013) Influence of imaging and
histological factors on prostate cancer detection and localisation on
multiparametric MRI: a prospective study. Eur Radiol 23:2019–2029
13. Barentsz JO, Richenberg J, Clements R et al (2012) ESUR prostate
MR guidelines 2012. Eur Radiol 22:746–757
14. Haider MA, Davidson SRH, Kale AV et al (2007) Prostate
gland: MR imaging appearance after vascular targeted photo-
dynamic therapy with palladium-bacteriopheophorbide.
Radiology 244:196–204
15. Huang Z, Chen Q, Trncic N et al (2004) Effects of Pd-
bacteriopheophorbide (TOOKAD)-mediated photodynamic therapy
on canine prostate pretreated with ionizing radiation. Radiat Res 161:
723–731
16. Barret E, Ahallal Y, Sanchez-Salas R et al (2013) Morbidity of focal
therapy in the treatment of localized prostate cancer. Eur Urol 63:
618–622
Insights Imaging (2014) 5:697–713 713
